Sorrento Presents Preliminary Results of STI-2020 Against COVID-19

 Sorrento Presents Preliminary Results of STI-2020 Against COVID-19

Sorrento Presents Preliminary Results of STI-2020 Against COVID-19

Shots:

  • The company presents the ongoing program of SARS-CoV-2 mutation surveillance for STI-2020 currently in pre/ clinical development for COVID-19
  • The data provides evidence of maintained binding potency in in vitro assays including the Spike amino acid changes found in SARS-CoV-2 viruses of the B.1.1.7 lineage, identified in the UK
  • Additional neutralizing Abs were identified that bind strongly to the B.1.1.7 & B.1.351 spike proteins and are under analyses for neutralization activities both in vitro and in vivo. Sorrento to unveils early in vitro results of diminished STI-2020 binding potency in assays including Spike proteins derived from viruses of the B.1.351 lineage, identified in SA

Click here ­to­ read full press release/ article | Ref: Sorrento | Image: Analyze Markets

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post